The NEK6 (NIMA-related kinases 6) is reported to play po-tential roles in tumorigenesis. Although it is suggested to function in several cellular pathways, the underlying mechanism in tumorigenesis is still largely unknown. In the present study, we discovered interaction of NEK6 with Smad4, a key member of transforming growth factor beta (TGF) pathway. Over-expression of NEK6 in hepatocellular carcinoma (HCC) cell lines suppresses TGF-mediated transcription activity in a kinase activity-dependent manner. In addition, NEK6 suppresses the cell growth arrest induced by TGF. Mechanically, NEK6 blocks nuclear translocation of Smad4, which is essential for TGF  function. Moreover, we identified that NEK6 could be regulated by TGF and hypoxia. 
INTRODUCTION
Human NIMA-related kinases is a family of 11 members, which are implicated in mitotic control (1) . During the mitotic process, NEK6 is phosphorylated and activated by NEK9, forming a mitotic cascade required for normal spindle organization and mitotic progression (2) . NEK6 inhibits the premature senescence induced by p53 or anticancer drug, and is also identified as a target of cell cycle checkpoint following DNA damage (3) (4) (5) . In cancers, the expression and kinase activity of NEK6 are up-regulated and are strongly associated with the advanced stage in gastric and liver cancers (6, 7) . Deregulation of NEK6 expression affects cell growth, apoptosis, transformation and tumorigenesis (8, 9) . However, the underlying mechanism is not fully understood. Canonical TGF signaling pathway is activated upon binding of TGF family members to type II TGF receptor (TRII).
Subsequently, TRII heterodimerizes and phosphorylates type I receptor (TRI), which phosphorylates the downstream R-Smads (Smad2 and Smad3). Phosphorylated R-Smads, together with the Co-Smad (Smad4), translocates into nucleus, binds to the "CAGA" consensus sequence, and regulates the transcription of target genes (2) . TGF can function as both tumor suppressor and promoter. In benign epithelia and many early-stage tumors, TGF is a potent inducer of growth arrest. However, TGF promotes cell motility, invasion, and metastasis in advanced tumors (3) .
In the current study, we identified inhibitory role of NEK6 on TGF pathway by interfering with nuclear translocation of Smad4. NEK6 itself is negatively regulated by TGF pathway, and is positively regulated by hypoxia. Therefore, our results suggest that deregulated NEK6 facilitate tumorigenesis via inhibition of TGF pathway and NEK6 may serve as a novel target for cancer therapy.
RESULTS AND DISCUSSION

NEK6 interacts with Smad4 and suppresses TGF-mediated transcription
To study the role of NKE6 in tumorigenesis, we searched the potential NEK6 interacting proteins from BioGRID beta database (http://www.thebiogrid.org), a protein-protein interaction networks in mammalian cells (13) . We found that several key members in TGF pathway, including Smad4, TGFBR1 and Smurf2, were indicated to interact with Nek6 in Mus Musculus. We hypothesized that human NEK6 may function in TGF pathway through its interaction with human Smad4, TGFBR1 and Smurf2. To confirm this hypothesis, interaction between NEK6 and these proteins was examined by co-immunoprecipitation assays. We showed that Smad4 was co-precipitated with NEK6 both in vitro and in vivo (Fig. 1A and B ), but not TGFBRI or Smurf2 (data not shown). This interaction was also confirmed by GST pull-down assay (Fig. 1C) . Thus, these results suggest interaction of Smad4 with NEK6. We have considered other members in Smad family, including Smad2 and Smad3 in TGF pathway, and Smad1 and Smad5 in BMP pathway, since Smad family members have two conservative Mad homologous, which were also reported to be indispensable in interaction with other proteins. However, we were not able to find additional interaction between these family members with human NEK6. http://bmbreports.org Subsequently, we investigated the role of NEK6 in TGF pathway by luciferase assay in HCC cell line Hep3B. We found that transcription of (CAGA)9 MLP-Luc, an artificial TGF/-Smad-responsive reporter, could be significantly induced by either TGF1 stimulation or transfecting Smad4 in a dose-dependent manner. However, in the presence of NEK6, transcription of reporter gene was significantly inhibited (Fig. 1D, E) . Interestingly, the kinase dead mutation of NEK6 not only abolished its suppressive role, but also behaved as an activator. The possible reason for such a behavior could be due to its dominant negative role that might have interfered with the endogenous NEK6.
NEK6 inhibits TGF-induced cell growth arrest by targeting downstream proliferation-associated genes
Furthermore, we examined the role of NEK6 in regulating the transcription of TGF/Smad downstream target genes. As shown in Fig. 2A , the up-regulation of DAPK1, p27, p21, and Smad7, and the down-regulation of c-myc and cdc25A induced by TGF1 were both inhibited by NEK6 in a kinase activity-dependent manner. Two classes of anti-proliferative genes are known to be induced by TGF and account for their cell growth arrest function. The first class is the Cdk-inhibitory responses that include the up-regulation of p15, p21, and p27, and the down-regulation of cdc25A. The second class is the down-regulation of c-myc observed in most cell types (4). Since NEK6 inhibited the transcriptional regulation of these genes, we hypothesized that NEK6 may play a suppressive role in TGF-induced cell growth arrest. Thus, we established control (C1 and C2) and Z cell line SMMC-7721. Expression of NEK6 was confirmed by Western blotting with the indicated antibodies (Fig. 2B) . Interestingly, we were unable to get NEK6 kinase dead stable cell lines, probably due to its indispensable role in cell proliferation (8) . Stable cell lines were cultured in medium with or without TGF1 (10 ng/ml) for 5 days and the cell growth was detected with cell proliferation assay. As shown in Fig. 2C , control cells were inhibited by 40.23% ± 2.35% and 41.31% ± 4.75 (C1 and C2 respectively) when compared to the non-treated cells,. While in the case of NEK6 overexpressed cells, the inhibition was attenuated by 61.17% ± 5.41% and 63.11% ± 2.75% (N11 and N38 respectively). Cell cycle analysis revealed that over-expression of NEK6 reversed the increase in cell numbers in G1 phage and decrease in cell numbers in S phase induced by TGF1 (Fig. 2D ).
NEK6 blocks TGF-induced Smad4 nuclear translocation
Further research is needed to explore the mechanism accounting for the antagonistic role of NEK6 in TGF pathway. One of the possibilities is that NEK6 may interfere with the nuclear translocation of Smad4. As shown in fig. 3A , Smad4 was translocated into nuclear in cell line C1 following TGF1 treat-http://bmbreports.org BMB Reports ment, while its translocation was blocked in cell line N38. In addition, we performed the nuclear and cytosolic fractionation assay from TGF1 treated C1 and N38 cells. Consistently, nuclear accumulation of Smad4 upon TGF1 treatment was attenuated in N38 cell line, when compared with the control C1 cell line (Fig. 3B) . In order to determine kinase activity of NEK6 for its role in nuclear translocation of Smad4, we transiently transfected the control vector, vector expressing wild type or kinase dead mutant of NEK6 into Hep3B cells, and performed the cell fractionation assay. As shown in fig. 3C , the kinase dead mutant of NEK6 abolished the nuclear translocation of Smad4 after TGF stimulation. It was intriguing to observe that kinase dead mutant of NEK6 had a higher ratio of Smad4 in nuclear to cytoplasm than cells expressing control vector even in non-treated cells. This result displays dominant negative role of kinase dead NEK6, which was consistent with our data from luciferase assay ( Fig. 1D and E) . These results suggest that NEK6 suppresses TGF signaling pathway by blocking nuclear translocation of Smad4 in a kinase activity dependent manner. However, the underlying mechanism is unknown. Since NEK6 is a serine/threonine kinase, we examined whether Smad4 would be phosphorylated at its serine/threonine sites. We transfected Hep3B cells with wild type or kinase dead NEK6 and enriched endogenous Smad4 by immunoprecipitation. Anti-phosphoserine/threonine antibody was used to evaluate the phosphorylation status of Smad4. Interestingly, when wild type NEK6 caused an obvious elevation of Smad4 phosphorylation, kinase dead construct also caused a slightly elevation (Fig. 3D ). This could be a result of balance between direct and indirect role of NKE6 kinase activity. As Smad4 has 40 serine sites and 29 threonine sites, NEK6 may phosphorylate only some of them, and kinase dead construct could abolish basal phosphorylation at these sites due to its dominant negative role. Hence, it is possible that other kinases could have led to phosphorylation of remaining sites in Smad4. When these kinase activities are affected by NEK6 kinase, for example inhibition by NEK6, a reduction in phosphorylation level of Smad4 could be observed. On the contrary, kinase dead construct may release inhibition of such kinases and then promote http://bmbreports.org further phosphorylation of Smad4. Further studies as well as prediction based on database are needed to confirm this hypothesis. Also, these results could not rule out the notation that NEK6 may activate other partners in NEK6-Smad4 complex, which results in retention of SMAD4 in cytoplasm.
NEK6 is down-regulated by TGF and up-regulated by hypoxia
Based on the potential function of NEK6 in regulating the TGF pathway in cancers, we further investigated the factors that may regulate the expression of NEK6. We retrieved 2500bp of NEK6 promoter (Chr9 127018040-127020539) and searched for transcription factor binding sites through TFD database (http://www.ifti.org/). We found one potential TGF responsive binding site (from -1754 to -1762bp), which contained the characteristic CAGA box (16) . As shown in Fig.  4A -C, both mRNA and protein of NEK6 were down-regulated in SMMC-7721 and Hep3B cells upon TGF1 treatment. Protein expression of c-myc was used as a positive control of TGF1 treatment. These data suggest a mutual regulation between TGF pathway and NEK6, which is similar to Smad7, an antagonist and target gene of TGF/Smad pathway (17) .
In addition to the TGF responsive binding site, we found two potential hypoxia inducible factor (HIF) binding sites, named as hypoxia responsive elements (HRE). As shown in Fig. 4D , NEK6 transcription was induced significantly by hypoxia (1% O2), and was reduced to normal after normoxia culture (21% O2) for additional 24 hours. In addition, we treated Hep3B and SMMC-7721 cells with desferrioxamine (DFO), which mimicked hypoxia induction of HIFα [19] . Both NEK6 mRNA and protein were significantly up-regulated following the treatment. Induction of HIFα and VEGF were used as positive controls of hypoxia treatment ( Fig. 4E-G) . As a common feature of tumor microenvironments, hypoxia promotes malignant progression or transformation of tumors. Even when the solid tumors are in their early stages, they would contain acute and chronic hypoxia (5) . In these stages, NEK6 could be up-regulated by hypoxia, attenuate cell growth arrest induced by TGF through regulation of related target genes, and create a favorable growth condition for tumor cells. Suppressed TGF signaling further enhances the expression of NEK6, which will strengthen its tumor-promoting role. We found that NEK6 was significantly up-regulated in HCC tumors with portal vein tumor thrombus and HCC cell lines with strong metastasis capability (Data not shown). Consequently, it is proposed that NEK6 could be a potential target for cancer therapy in the early stages of tumor development. Function of NEK6 in the advanced stages of tumors needs further investigation, since at this stage; TGF promotes cell motility, invasion, and metastasis and acts as a tumor promoter.
MATERIALS AND METHODS
Cell cultures
Hep3B and SMMC-7721 cells were purchased from Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China) and maintained in Dulbecco's modified Eagle's medium (Gibco) supplemented with 10% (v/v) fetal bovine serum (PAA) at 37 o C in a humidified incubator containing 5% CO2.
Immunoprecipitaion assay
Hep3B cells were transfected with indicated plasmids using Lipofectamine (Invitrogen) according to the manufacturer's protocols. Forty-eight hours later, 10 6 cells were lysed with cold lysis buffer [5 mM EDTA, 0.5% NP-40, 0.1 mM phenylmethane sulphonyl-flouride (PMSF), 10 M pepstatin A, 10 M leupeptin and 25 g/ml aprotinin]. Cell lysates were then collected and pre-cleared by 20 l protein G Plus/protein A agarose beads (Amersham) at 4 o C for 1 hour with rotation. Then, pre-cleared cell lysates were incubated with 40 l protein G Plus/protein A agarose beads and 1 g anti-myc mono-clonal antibody (mAb) http://bmbreports.org BMB Reports at 4 o C for 6 hours with rotation. Agarose beads were collected and washed five times with lysis buffer, and then the samples were subjected to SDS-PAGE and Western blot assay. For in vivo immunoprecipitation, 5 g anti-NEK6 mAb (Sigma) and mouse IgG (Sigma) were used. Whole cell lystes and precipitated complex were immunoblotted by anti-NEK6 mAb and anti-Smad4 antibody (Epitomics).
GST pull-down assay
Glutathione S-transferase (GST) fused Smad4 protein was kindly provided by Dr Jian An (Fudan University, China). Cell lysates from Hep3B cells expressing His-tagged NEK6 were incubated with 10 g GST-Smad4 or 25 g GST proteins, together with 40 l glutathione-S-Sepharose beads (Amersham) in lysis buffer at 4 o C for 6 hours. Sepharose beads were then collected and washed with lysis buffer for three times. Samples were then analyzed by SDS-PAGE and Western blot and precipitated GST-protein was determined by Coomassie brilliant blue G250 staining.
Luciferase assay
Hep3B cells were transfected with plasmid combination including (CAGA)9 -MLP-Luc. Cells were lysed 36 hours following transfection, and luciferase activities were determined by using the Dual Luciferase reporter system (Promega) on a Lumat LB 9507 luminometer (Berthold). Values were normalized with the renilla luciferase activity expressed from pRL--CMV. In TGF1 stimulation assay, cells were serum starved for 8 hours, then treated with TGF1 (5 ng/ml or 10 ng/ml) for additional 5 hours before harvest.
Plasmids and cytokines
Preparation of pCMV-Myc-NEK6 and pcDNA3.1-NEK6 has been described previously (19) . The kinase dead mutant NEK6--K74MK75M was generated by point mutagenesis. Human Smad4 plasmid and (CAGA)9 MLP-luciferase reporter plasmid were kindly gifted by Dr Jian An (Fudan University, China). Human recombinant TGF1 was purchased from Peprotech.
Western blot
Protein samples separated by SDS-PAGE were electro-transferred onto nitrocellulose membranes (Amersham). Then membranes were blocked with 5% non-fat milk blocking solution and incubated with specific primary antibody at 4 o C overnight, followed by incubation with horseradish peroxidase (HRP)-labeled secondary antibody (Santa Cruz). Signals were visualized by enhanced chemiluminescence reagents (Santa Cruz). Anti--actin, anti-myc, anti-HA, anti-his, anti--tubulin, anti-HIF, anti-c-myc, and anti-NEK6 antibodies were purchased from Sigma. Anti-Smad4 and anti-Max antibodies were purchased from Epitomics. Anti-phosphoserine/threonine antibody was purchased from Abcam.
Quantitative real-time PCR
Total RNA was extracted from cells with Trizol reagent (Invitrogen) and the first-strand cDNA was synthesized using a reverse transcription kit (Invitrogen) following the manufacturer's instructions. Real-time PCR was performed by using SYBR Green PCR master mix (TOYOBO) on a Light Cycler 480II detection System (Roche). Gene expression was normalized to that of the housekeeping gene 2-microglobulin (2-MG). 
Selection of stable cell lines
SMMC-7721 cells were transfected with pcDNA3.1-NEK6 or control vector. Twenty-four hours later, cells were collected and seeded into 100-mm dishes. Subsequently, cells were selected in the presence of 800 g/ml G418 for two weeks. Cell colonies were isolated and subjected to Western blot for NEK6 expression.
Cell Proliferation assay
Cells were seeded in 96-well plates at the density of 1.0×10 3 cells per well; and cultured in medium with or without 10 ng/ml TGF1. Fresh medium was changed every 2 days. Five days later, cells were subjected to 3-(4,5-dimethyl-thiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H -tetrazolium (MTS) assay (Promega) according to the manufacturer's instructions. Spectrophotometric absorbance at 490 nm was read by a microtiter reader (HITACHI).
Flow cytometry analysis
Cells were harvested, washed with ice-cold phosphate-buffered saline (PBS) and then incubated with staining buffer (PBS with 0.03% TritonX-100, 50 g/ml propidium iodide, 100 g/ml RNase) for 10 minutes at room temperature. DNA content of cells was analyzed with FACS Calibur (BD Biosciences). Cell cycle distribution was analyzed with ModFit.
Immunofluorescence microscopy
Cells were serum starved for 8 hours and then treated with normal medium with 10 ng/ml TGF1 for additional 5 hours. Then cells were fixed with 4% paraformaldehyde for 10 mi-nutes and permeabilized with 0.2% Triton X-100 for 5 minutes at room temperature. Samples were washed thrice with TBS (50 mM Tris-HCl pH7.4, 150 mM NaCl) and blocked with blocking buffer (PBS with 1% horse serum, 1% BSA, 0.02% NaN3) for 1 hour. Next, cells were incubated with the combination of 1:200 (v/v) diluted anti-myc mAb and anti-Smad4 poly-clonal antibody at 4 o C overnight. Cells were then washed three times with TBS and incubated with 1:5000 (v/v) diluted Cy3-conjugated rat anti-mouse IgG and FITC-conjugated goat anti-Rabbit IgG for 45 minutes. Cells were counterstained with DAPI for 20 minutes and mounted on slides for confocal microscopy analysis by LSM700 laser scanning microscope (Carl Zeiss).
Preparation of cytoplasmic and nuclear extracts
Ten million cells were suspended in 0.5 ml ice-cold lysis buffer A (20 mM HEPES, pH 7.9, 50 mM KCl, 1.5 mM MgCl2, 0.05% Nonidet P-40, 1 mM DTT, 8 ng/ml aprotinin, 2 ng/ml leupeptin, and 1 mM PMSF) for 10 minutes. Then, cytoplasmic fraction was collected by centrifugation at 6500 rpm at 4 o C for 10 minutes, and the nuclear pellet was washed three times with lysis buffer A and re-suspended in 0.3 ml ice-cold buffer B (20 mM HEPES, pH 7.9, 0.4 M NaCl, 1.5 mM MgCl2, 25% glycerol, 1 mM DTT, 8 ng/ml aprotinin, 2 ng/ml leupeptin, and 1 mM PMSF) for 30 minutes. Subsequently, the samples were centrifuged at 12,000 rpm at 4 o C for 30 minutes, and the supernatant was collected as nuclear extract.
Statistical analysis
Statistical significance was examined with two-tailed Students t-test. Results with P values less than 0.05 were considered significant.
